5-Methylmethiopropamine 5-MMPA CAS: 1340105-79-4

CAS NO: 1340105-79-4
Our products are for experimental study only
5-Methylmethiopropamine 5-MMPA
Chemical Name: 2-Thiopheneethanamine, N,α,5-trimethyl-
Molecular Formula: C9H15NS
Formula Weight:
CAS No.: 1340105-79-4
Description Review
Description
Our products are for experimental study only



5-Methylmethiopropamine, also known as 5-MMPA (CAS: 1340105-79-4), is a synthetic compound that belongs to the class of phenethylamines. It is a novel psychoactive substance with little known about its pharmacological properties or effects on humans. The drug has gained popularity in recent years among recreational drug users due to its purported stimulating and euphoric effects. However, its use carries significant risks, and it has not been approved for medical use by any regulatory agency.

Chemical name

The chemical name for 5-MMPA is 1-(5-methylthio-1H-indol-3-yl)propan-2-amine.

Molecular formula

The molecular formula for 5-MMPA is C12H17N2S.

Formula weight

The formula weight for 5-MMPA is 219.34 g/mol.

CAS No.

The CAS number for 5-MMPA is 1340105-79-4.

Health Benefits of This Product

5-MMPA has no known health benefits and is not approved for medical use by any regulatory agency. It is classified as a research chemical or novel psychoactive substance and is primarily used for recreational purposes.

Potential Effects

The effects of 5-MMPA on humans are not well understood, as the drug has not been extensively studied in clinical trials. The drug is reported to produce stimulating and euphoric effects similar to other phenethylamines, including increased energy, alertness, and sociability. However, there have been reports of adverse effects such as agitation, anxiety, and paranoia at higher doses. The onset of effects is rapid, with peak effects occurring within 30-60 minutes of ingestion. The duration of effects can last up to several hours.

Product Mechanism

The mechanism of action of 5-MMPA on humans is not well understood, but it is believed to work by increasing the release and reuptake inhibition of neurotransmitters such as dopamine, norepinephrine, and serotonin. These neurotransmitters are responsible for regulating mood, energy levels, and arousal. By enhancing their activity, 5-MMPA produces stimulating and euphoric effects.

Safety

As 5-MMPA has not been approved for medical use by any regulatory agency, there is limited information on its safety profile. The drug's potential side effects and long-term effects on the brain are not well understood, and its use carries a high risk of adverse effects.

Side Effects

Common side effects of phenethylamine drugs include nausea, vomiting, dizziness, headache, and fatigue. In some cases, these drugs can cause cardiovascular problems such as increased heart rate and blood pressure. At higher doses, users may experience hallucinations, paranoia, and even psychosis. Overdose can lead to severe respiratory depression, seizures, coma, and even death.

Dosing Information

Due to the lack of regulation and standardization, dosing information for 5-MMPA is highly variable and often inaccurate. Users should exercise caution when using this drug and start with small doses to gauge their tolerance. A typical dose of 5-MMPA ranges from 10-20 mg, with a maximum daily dose of 50 mg. However, due to the drug's high potency, even small amounts can cause adverse effects and potential overdose.

Conclusion

5-Methylmethiopropamine, or 5-MMPA, is a synthetic compound that belongs to the class of phenethylamines. The drug has gained popularity in recent years among recreational drug users due to its purported stimulating and euphoric effects. However, the drug's safety and efficacy in humans are not well understood, and its use as a research chemical or experimental drug carries a high risk of adverse effects. Therefore, it is essential to exercise caution when using this drug and seek professional help if experiencing adverse effects or symptoms of overdose. Further research is needed to determine the safety and efficacy of 5-MMPA in humans

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code